Last reviewed · How we verify

NCT06969378

Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease

Not yet recruiting NA Last updated 13 May 2025
What this trial tests

NA trial testing Pulsed field ablation using a pentaspline ablation catheter in Atrial Fibrillation in 30 participants. Not yet recruiting.

Timeline
1 July 2025
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorBoston Children's Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date1 July 2025
Primary completion30 June 2026
Estimated completion30 June 2026

Drugs / interventions tested

Conditions studied

Sponsor

Boston Children's Hospital

Who can join

18 and older, any sex, with Atrial Fibrillation or Atrial Tachycardia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-arm intervention trial whereby we will test the safety and efficacy of performing pulmonary vein isolation (PVI) using pulsed field ablation (PFA) in adult patients with congenital heart disease (CHD) who are presenting for atrial tachycardia (AT) ablation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Boston Children's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06969378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing